Research Library › Incretin & Amylin
Mazdutide (development codes LY3305677 and IBI362) is a synthetic oxyntomodulin-analog peptide designed to activate both the GLP-1 receptor and the glucagon receptor. It was created by Eli Lilly and Company, which licensed it to Innovent Biologics for China in 2019. As of October 2026 it is approved by China’s NMPA (2025) but is not FDA-approved, and Lilly’s studies outside China are at Phase II.
Key facts
| Type | Synthetic peptide; mammalian oxyntomodulin (OXM) analog and GLP-1/glucagon receptor dual agonist |
|---|---|
| Other names | LY3305677 (Lilly), IBI362 (Innovent), OXM3 |
| Developed by | Eli Lilly and Company (originator); Innovent Biologics (China, under licence) |
| First described | Licensed to Innovent as OXM3 in August 2019; first clinical publication 2021 |
| Designed target | GLP-1 receptor and glucagon receptor |
| Regulatory status (Oct 2026) | Approved in China (NMPA, June and September 2025); not FDA-approved; Phase II in Lilly studies outside China |
Who developed it
Mazdutide was discovered at Eli Lilly and Company, where it carries the code LY3305677. On 22 August 2019 Innovent Biologics, a Chinese biotechnology company, announced that Lilly had granted it a licence to develop and potentially commercialize the molecule in China. At that point the compound was called OXM3 and was already in clinical testing [1].
Innovent runs the Chinese program under the code IBI362, while Lilly holds the rights elsewhere [1, 3]. The two companies have therefore run largely separate programs: Innovent’s Phase III trials enrolled Chinese adults, while Lilly has tested the same molecule under its own code in studies registered outside China [3, 6].
Mazdutide is the international nonproprietary name used for the compound in both companies’ later trial registrations and in Innovent’s 2025 approval announcements, replacing the OXM3, IBI362 and LY3305677 codes in public communications [4, 5, 6].
Structure and design
Innovent describes mazdutide as a mammalian oxyntomodulin analog [3, 4]. Oxyntomodulin is a natural gut peptide that interacts with both the GLP-1 receptor and the glucagon receptor, and mazdutide was engineered as a longer-acting molecule designed to bind both receptors [2].
Its proposed mechanism, combined signaling at both receptors, places it in the same broad research class as Boehringer Ingelheim’s survodutide. Innovent has called mazdutide the first approved dual GCG/GLP-1 receptor agonist [4].
Research history
- August 2019: Lilly licenses OXM3 to Innovent for China [1]
- 2021: First Phase Ib study of IBI362 (LY3305677) in Chinese adults published in EClinicalMedicine [2]
- January 2024: Innovent reports four Phase III trials under way in China: GLORY-1 and GLORY-2 in overweight and obesity, and DREAMS-1 and DREAMS-2 in type 2 diabetes [3]
- June 2025: NMPA approves mazdutide in China for chronic weight management [4]
- September 2025: NMPA approves a second indication, glycemic control in adults with type 2 diabetes [5]
Regulatory status as of October 2026
China’s National Medical Products Administration (NMPA) approved mazdutide in June 2025 for chronic weight management in adults with obesity or overweight, as an adjunct to diet and exercise. In September 2025 the agency approved it for glycemic control in adults with type 2 diabetes [4, 5]. These approvals apply only in China and were granted on the basis of Innovent’s Chinese Phase III program [3, 4, 5].
Mazdutide is not approved by the FDA or the European Medicines Agency. Outside China, Lilly lists mazdutide (LY3305677) in Phase II studies in adults with obesity or overweight [6].
In August 2026 the FDA issued warning letters to several online sellers of peptides labeled “research use only,” and mazdutide was among the products named [7].
About this reference page
Kalibra Labs does not currently supply Mazdutide. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Who makes mazdutide?
Mazdutide was discovered by Eli Lilly and Company. Innovent Biologics develops and markets it in China under a licence signed in 2019 [1, 4].
Is mazdutide FDA approved?
No. As of October 2026 mazdutide is approved only in China, where the NMPA cleared it in 2025; it is not FDA-approved and remains investigational elsewhere [4, 5, 6].
What are IBI362 and LY3305677?
They are development codes for mazdutide: LY3305677 is Lilly’s code and IBI362 is Innovent’s [2, 3].
What is mazdutide based on?
It is an analog of oxyntomodulin, a natural gut peptide that interacts with both the GLP-1 and glucagon receptors [3, 4].
Has the FDA taken action on unapproved mazdutide?
Yes. Mazdutide was among the products named in FDA warning letters to online “research use only” peptide sellers in August 2026 [7].
Sources
- Innovent Biologics. Voluntary announcement: license agreement with Eli Lilly and Company for OXM3 in China. HKEX filing, 22 Aug 2019. Link
- Ji L, Jiang H, An P, et al., Qian L. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021;39:101088. doi:10.1016/j.eclinm.2021.101088. Link
- Innovent Biologics. Voluntary announcement on mazdutide (IBI362) Phase 3 GLORY-1 study. HKEX filing, 9 Jan 2024. Link
- Innovent Biologics. Innovent announces mazdutide, first dual GCG/GLP-1 receptor agonist, received approval from China's NMPA for chronic weight management. Press release, 27 Jun 2025. Link
- Innovent Biologics. Innovent announces mazdutide received approval from China's NMPA for glycemic control in adults with type 2 diabetes. Press release, 19 Sep 2025. Link
- Eli Lilly and Company. Lilly Trials: A study of LY3305677 (mazdutide) compared with placebo in adult participants with obesity or overweight, Phase II, NCT06124807. Link
- ArentFox Schiff. RUO-ined: Five peptide vendors learn that 'research use only' is not a legal strategy. 18 Sep 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
